||Last Updated: Nov 17th, 2006 - 22:35:04
Phase Ib Trial Is Evaluating Bavituximab Administered With Common Chemotherapy Regimens
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus (HCV) infection, today announced initiation of patient treatment in its Phase lb clinical trial to evaluate its lead anti-phospholipid immunotherapy agent bavituximab given in combination with common cancer chemotherapy agents. The trial is expected to enroll up to 12 patients at three clinical sites in India.
Nov 17, 2006, 22:32
Complete Inhibition of Viral Replication in H5N1 In Vivo Model by Bavituximab
Peregrine Pharmaceuticals, a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that its lead anti-viral compound bavituximab (formerly Tarvacin) completely inhibited replication of a laboratory strain of the H5N1 virus, commonly known as avian flu, in fertilized chicken eggs, an in vivo model for influenza anti- viral activity. These preliminary findings will be reported today at the 106th general meeting of The American Society for Microbiology (ASM) in Orlando, Florida by Dr. Philip Thorpe, a member of the Peregrine Scientific Resource Board and professor of pharmacology at the University of Texas Southwestern Medical Center at Dallas. Bavituximab, a monoclonal antibody with unique anti-viral and anti-cancer properties, has already demonstrated good tolerability in a Phase l trial in patients with HCV infection.
May 25, 2006, 13:09
FDA Gives Tentative Approval to Abacavir
The Food and Drug Administration (FDA) today announced the tentative approval of generic abacavir (a-BAK-a-veer) sulfate tablets manufactured by Aurobindo Pharma LTD. of Hyderabad, India. Abacavir sulfate tablets are the first generic version of the already approved Ziagen Tablets, an anti-HIV medication manufactured by GlaxoSmithKline. This product will now be available for consideration for purchase under the President's Emergency Plan for AIDS Relief.
May 20, 2006, 03:01
Telbivudine emerging as a potent new treatment option for Hepatitis B
Novartis Pharma AG and Idenix Pharmaceuticals, Inc. announced today that the phase III GLOBE registration trial for telbivudine successfully reached its primary, composite efficacy endpoint of therapeutic response at one year in chronic hepatitis B patients.
Jul 29, 2005, 22:25
New Saquinavir Formulation Simplifies Dosing Regimen for HIV Patients
Roche announced the European marketing approval for its new 500 mg formulation of Invirase (saquinavir mesylate), an effective and well tolerated protease inhibitor used in the treatment of HIV infection. The new 500 mg tablet will simplify the dosing regimen for patients by reducing the daily tablet count by more than half, from five tablets twice-daily to two tablets twice-daily.
May 30, 2005, 20:48
CPG 10101 Shows Significant Antiviral Activity in Chronic Hepatitis C Patients
Coley Pharmaceutical Group, Inc today announced at the Digestive Disease Week conference that Actilon(TM) (CPG 10101) was relatively well tolerated and showed antiviral activity in the company's Phase Ib clinical study in chronic Hepatitis C patients.
May 23, 2005, 11:21
Further Studies Needed for Tipranavir
Boehringer Ingelheim's Aptivus should be approved for treatment resistant HIV patients, but further studies are needed to guide use of the drug, FDA's Antiviral Drugs Advisory Committee recommended May 19.
May 20, 2005, 08:27
Comparator Arm Suboptimal in Tipranavir Trial
Patient resistance to comparator protease inhibitors used in Boehringer Ingelheim's Aptivus (tipranavir) pivotal trials will likely be a central issue in the Antiviral Drugs Advisory Committee's review of the HIV agent.
May 19, 2005, 08:48
Telbivudine Demonstrates Advantages Over Lamivudine in HBeAg-positive Chronic Hepatitis B
Idenix Pharmaceuticals, Inc. today announced the presentation of interim two-year results from an extended-treatment phase IIb clinical trial for telbivudine demonstrating continuing advantages compared to lamivudine across key efficacy endpoints through two years of treatment in HBeAg-positive chronic hepatitis B patients.
May 17, 2005, 08:53
VX-950 : An Oral Hepatitis C virus Protease Inhibitor Shows Potent Antiviral Activity
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results that indicate that the investigational oral hepatitis C virus (HCV) protease inhibitor VX-950 was well-tolerated and demonstrated potent antiviral activity in a Phase Ib clinical trial.
May 10, 2005, 20:06
Baraclude™ (Entecavir) For Treatment Of Chronic Hepatitis B approved by FDA
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved Baraclude™ (entecavir).
Mar 31, 2005, 21:26